Coronary embolism in a patient with mitral valve prosthesis： successful management with tirofiban and half-dose tissue-type plasminogen activator

Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management o...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2007-12, Vol.120 (24), p.2321-2322
Main Authors: Atmaca, Yusuf, Ozdol, Cagdas, Erol, Cetin
Format: Article
Language:English
Subjects:
Coronary Thrombosis - drug therapy
Coronary Thrombosis - etiology
Embolism - drug therapy
Embolism - etiology
Heart Valve Prosthesis - adverse effects
Humans
Male
Middle Aged
Mitral Valve - surgery
Tissue Plasminogen Activator - administration & dosage
Tyrosine - administration & dosage
Tyrosine - analogs & derivatives
二尖瓣修复术
冠状动脉栓塞
心脏病
血纤维蛋白溶酶原
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronary embolism has been considered as a rare cause of coronary occlusion. Prosthetic heart valve is an infrequent cause of this condition. The exact incidence of coronary embolization in patients with prosthetic heart valves is not well known. Furthermore, the effective treatment and management of coronary emboli in this setting remains unknown. It is the purpose of this paper to report the successful management of a case of coronary embolism with half-dose tissue-type plasminogen activator （tPA） and tirofiban given intravenously in a patient with initial valve prosthesis.
ISSN:0366-6999
2542-5641
DOI:10.1097/00029330-200712020-00033